In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kyowa Kirin Co., Ltd.

https://www.kyowakirin.com/

Latest From Kyowa Kirin Co., Ltd.

Label Woes For GSK’s Jesduvroq Dampen US Anemic Kidney Disease Approval

The UK major’s Jesduvroq has become the first drug of its class to win US approval for anemic kidney disease but significant label restrictions have left some analysts lukewarm on its sales potential.

Approvals Commercial

End Of US FDA’s Very Fast Reviews? 2022 Novel Approvals Stayed Close To PDUFA Timeframes

Moderation was a theme of the year in novel approvals, as CDER’s median review time rose for the first time in five years and even the center’s fastest approval took more than seven months. A Pink Sheet infographic breaks down which review pathways did the best last year. 

Pink Sheet Perspectives US FDA Performance Tracker

Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances

The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and experts reveal what they are most excited about on the technology front.

Scrip Asks Innovation

REMS Vendor Disruptions Prompt Greater US FDA Scrutiny

McKesson’s exit from the space forced sponsors to switch vendors managing their REMS programs, which in some instances affected patient access to drugs. Omnibus legislation requires GAO report and collection of public input on factors FDA should consider in reviewing vendor changes.

Drug Safety FDA
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Research, Analytical Equipment & Supplies
  • Pharmaceuticals
    • Nutraceuticals
    • Radiopharmaceuticals, Contrast Agents
  • Biotechnology
    • Drug Discovery Tools
  • Other Names / Subsidiaries
    • Archimedes Pharma Ltd.
    • Centus Biotherapeutics Ltd.
    • Daiichi Fine Chemical Co., Ltd.
    • Fujifilm Kyowa Kirin Biologics Co., Ltd.
    • Kirin Pharma Company, Limited
    • Kyowa Kirin Asia Pacific Pte. Ltd.
    • Kyowa Kirin Australia Pty Ltd
    • Kyowa Kirin International PLC
    • Kyowa Pharma Chemical Co., Ltd.
    • ProStrakan Group plc
    • Kyowa Kirin
    • Kyowa Kirin Frontier Co., Ltd.
    • Kyowa Hakko Kirin (Singapore) Pte. Ltd.
    • Kyowa Hakko Kirin Co., Ltd.
UsernamePublicRestriction

Register